News >

Damon Discusses Drug Development in AML

Caroline Seymour
Published: Friday, Oct 05, 2018

Lloyd Damon, MD

Lloyd Damon, MD
FLT3 and IDH1/2 mutations are two of many molecular targets that can be found in patients with acute myeloid leukemia (AML). Although there are FDA-approved agents available for those harboring such abnormalities, others are in development and quickly gaining traction, explained Lloyd Damon, MD.

State of the Science Summit™ on Hematologic Malignancies, Damon, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discussed novel therapies in AML with a focus on FLT3 and IDH1/2 inhibitors.

OncLive: Could you highlight the novel FLT3 inhibitors in the landscape?

Damon: We currently know over 90% of the genetic lesions involved in the pathogenesis of AML. One's individual genetic findings may direct you to genetic-based therapies that will facilitate entering remission with chemotherapy, or ultimate cure.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication